Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR dose comparison in Cushing's disease
NL-OMON39251Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pasireotide LAR in Corticotropin adenoma (ACTHoma) (2 arms), sponsored by Novartis. Primary endpoint: Proportion of patients with normalized mean urinary free cortisol at month 7 regardless of up-titration at month 4. Started Apr 2012; status: active, not recruiting.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on NL-OMON39251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39251.